Articles

Find an Article

Filter articles

Applied Filters

Showing 91 to 100 of 136 results

University of Manchester IP: walk the line

UK, US28-11-2014

By facilitating public access to the work being done, universities face the challenge of maintaining a balance between being transparent and commercialising IP. LSIPR spoke to the head of the University of Manchester IP about walking the fine line.

Tomato and Broccoli: patenting plant products

EU, Germany27-11-2014Franz-Josef Zimmer and Markus Grammel

The EPO’s Enlarged Board of Appeal is about to deliver its long-awaited final decision on the patentability of plants, in the hope that it will at least bring legal certainty to patentees and unfreeze pending appeals. Franz-Josef Zimmer and Markus Grammel of Grünecker report.

A bright future for AstraZeneca?

Sweden, UK, US03-11-2014

AstraZeneca has had a tough few years, with a clutch of patent expiries one of the most serious of its problems. So where does it go from here? To find out, LSIPR spoke to the Anglo-Swedish pharmaceutical company’s vice president of business development about the role IP is playing in its plans for future success.

LSIPR roundtable

UK, US30-09-2014

Earlier this month, the first LSIPR roundtable discussion took place in a London hotel, chaired by managing editor Martin Essex, with six invited experts and deputy editor 
Ed Conlon taking part. We’ll be publishing a special report on the event but, to whet your appetite, here’s how the discussion began—with a lively debate on the USPTO’s guidelines on patent-eligible subject matter in the wake of the Myriad and Mayo court decisions.

Productive partnerships: HemoShear's IP strategy

US01-08-2014

HemoShear creates systems for predicting human responses to drugs by applying its proprietary technology to human cells in the lab to make them behave the way they would in vivo. LSIPR found out about its strategy for protecting and developing its technologies.

Plumbing the depths: PharmaSea's search for new drugs

US07-07-2014

The PharmaSea project is working to make viable drug candidates of novel compounds found under the sea. LSIPR discovers how the EU-funded initiative does it.

Emerging opportunities in East Asia

Chile, Japan, South Korea20-06-2014

China, Japan and South Korea are three of the most developed markets in the world for pharmaceuticals but they still offer a wealth of opportunities for both innovators and generic drug companies. LSIPR looks at the protection available for those seeking to do business there.

The Bolar exemption: the need for agreement

EU, Germany, Poland20-06-2014Rafal Witek

There is no uniform interpretation of the scope of the Bolar exemption in Europe, but a CJEU opinion harmonising the issue may be on the way, says Rafal Witek.

Patent term: proceed with caution

US20-06-2014Gaby L. Longsworth and Eric K. Steffe

The effect of obviousness-type double patenting on patent term extension and patent term adjustment in the biotech and pharma industry needs careful consideration, as Gaby L. Longsworth and Eric K. Steffe report.

The Copaxone battle: an update

India30-04-2014Archana Shanker

Arguments over the term of the patents granted are at the heart of the Copaxone conflict, says Archana Shanker.

Showing 91 to 100 of 136 results

LSIPR